Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Adam Mead and Peter McHugh, who were awarded the title of full professor in the recent Recognition of Distinction.

This is a huge achievement and reflects the excellence of their research achievements and also their commitment to teaching and ‘good citizenship’ within our Institute and beyond.

Prof Adam Mead, Professor of Haematology, leads a team investigating how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. The overarching aim of his research group is to improve the management of myeloproliferative neoplasms (MPN), chronic myeloid leukaemia (CML) and related conditions through better characterisation and therapeutic targeting of malignant stem and progenitor cell populations. Adam is a Consultant Haematologist and an MRC Senior Clinical Fellow at the Radcliffe Department of Medicine.

Prof Peter McHugh, Professor of Molecular Oncology, researches DNA damage and repair mechanisms. His research group is interested in how these processes take place in normal, healthy cells, but also how they are used by cancer cells to resist treatment and repair their DNA. He is particularly interested in inter-strand crosslinks and a specific family of DNA repair nucleases. Peter is a Professor in the Department of Oncology.

Many congratulations as well to Dr Anindita Roy, now Associate Professor of Paediatrics Haematology (Department of Paediatrics); and Dr David Sims, now a University Research Lecturer (MRC WIMM Centre for Computational Biology and Radcliffe Department of Medicine).

Anindita Roy

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.